Skip to main content
Clinical Trials/NCT06180265
NCT06180265
Completed
Not Applicable

PRESEPSIN: Biomarker in the Early Diagnosis of Sepsis

University of Foggia1 site in 1 country90 target enrollmentFebruary 1, 2020
ConditionsSeptic Shock

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Septic Shock
Sponsor
University of Foggia
Enrollment
90
Locations
1
Primary Endpoint
incidence of mortality at 30-days
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (ICU) patient. Various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment.

No studies compared presepsin to procalcitonin and endotoxin in patients treated with by extracorporeal hemoperfusion with a polymyxin-B-adsorbing cartridge (PMX-HA).

Detailed Description

Intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (ICU) patient. Various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment. Particularly, endotoxin can be removed from the blood by extracorporeal hemoperfusion with a polymyxin-B-adsorbing cartridge (PMX-HA). No studies compared presepsin to procalcitonin and endotoxin in patients treated with PMX-HA. The investigators aim to evaluate the trend and prognostic value of presepsin versus procalcitonin and endotoxin in ICU patients with septic shock from complicated major abdominal surgery, treated with PMX-HA.

Registry
clinicaltrials.gov
Start Date
February 1, 2020
End Date
July 19, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Sponsor
University of Foggia
Responsible Party
Principal Investigator
Principal Investigator

Cotoia Antonella

Principal Investigator

University of Foggia

Eligibility Criteria

Inclusion Criteria

  • caucasian patients
  • patients undergoing laparoscopic major abdominal surgery

Exclusion Criteria

  • pregnancy,
  • organ transplantation,
  • palliative care
  • metastatic cancer
  • head trauma and polytrauma
  • coagulopathies
  • use of anticoagulants
  • neurological disease
  • autoimmune disease
  • thyroid disease.

Outcomes

Primary Outcomes

incidence of mortality at 30-days

Time Frame: up to 30 days

incidence of mortality

Study Sites (1)

Loading locations...

Similar Trials